Compare Amylx Pharmaceuticals Inc (AMLX) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs SoFi Technologies Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while SoFi Technologies Inc trades at $19 (market cap $24.09B). The key difference: SoFi Technologies Inc is far larger — about 12.2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | SOFI | |
|---|---|---|
Market Cap | $1.98B | $24.09B |
Sector | Health | Financials |
52-Week High | $18.70 | $32.21 |
52-Week Low | $7.64 | $15.15 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SoFi Technologies (SOFI) trades at $18.78, up 0.86% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $3.61B in 2025, though net income dipped to $481M. The company expanded its ETF lineup with SFYI and acquired AI investing agent Composer, driving positive media coverage. Support sits at $18, resistance at $19.
Outlook: SoFi's bank charter and digital expansion offer growth, but high P/E (41.73) and volatile cash flows pose risks. Analyst consensus target is $22.43 (17% upside), yet mixed ratings reflect execution concerns. Key risks include interest rate sensitivity and competitive fintech pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
